Allogene Therapeutics Launches New Underwritten Common Stock Offering

Allogene Therapeutics ( (ALLO) ) has shared an update.

On April 13, 2026, Allogene Therapeutics announced it had commenced an underwritten public offering of its common stock, marking a new effort to raise capital through the equity markets to support its business activities. In conjunction with the new offering, the company suspended sales under its existing at-the-market program with TD Securities and stated it will not resume such sales until a new prospectus or supplement is filed, signaling a shift in its near-term financing strategy and potentially affecting how current and prospective investors access its shares.

The most recent analyst rating on (ALLO) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.

Spark’s Take on ALLO Stock

According to Spark, TipRanks’ AI Analyst, ALLO is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and persistent negative free cash flow). Offsetting this are constructive technical momentum and encouraging clinical progress/catalysts (earnings call and new interim ALPHA-3 update), while valuation remains challenged due to negative earnings and no dividend support.

To see Spark’s full report on ALLO stock, click here.

More about Allogene Therapeutics

Allogene Therapeutics, Inc. is a biotechnology company, operating in the U.S., that focuses on developing and commercializing innovative therapies, with its primary activities centered around research, clinical development and related corporate financing in the life sciences sector. The company accesses capital markets to fund its operations and advance its pipeline of therapeutics for patients and healthcare stakeholders.

Average Trading Volume: 5,835,274

Technical Sentiment Signal: Buy

Current Market Cap: $663.1M

For an in-depth examination of ALLO stock, go to TipRanks’ Overview page.